Mi­cro­bio­me start­up sells off as­sets; Faron's PhI/II da­ta in bone mar­row can­cer; AM Phar­ma touts bio­mark­er re­sults

Mi­cro­bio­me start­up sells as­sets, goes dark: Fed­er­a­tion Bio sold some of its as­sets and erased its web­site three years since emerg­ing with $50 mil­lion. Kan­vas Bio­sciences, an­oth­er mi­cro­bio­me start­up, said Wednes­day that it bought two of Fed­er­a­tion’s in­ves­ti­ga­tion­al ther­a­peu­tics, a mi­cro­bial li­brary and oth­er IP. It al­so gained ac­cess to a cell bank­ing op­er­a­tion in South San Fran­cis­co and poached Fed­er­a­tion’s sci­ence chief Lee Swem, nam­ing him chief de­vel­op­ment of­fi­cer. Ven­rock, Hori­zons Ven­tures and oth­er firms had bankrolled Fed­er­a­tion’s plans to take gut bac­te­ria and poop to make ther­a­pies for in­flam­ma­to­ry bow­el dis­ease, a rare meta­bol­ic dis­or­der known as en­teric hy­per­ox­aluria and can­cer pa­tients who don’t ben­e­fit from cer­tain im­munother­a­pies. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER